Is COLL or CTOR more undervalued in 2026?

CirclFi compares Collegium Pharmaceutical, Inc. (COLL) and Citius Oncology, Inc. (CTOR) using 13 institutional-grade valuation models. COLL has a Quality of Company score of 9.2/10 while CTOR scores 3.4/10.

Which is a better buy — COLL or CTOR?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do COLL and CTOR valuations compare?

COLL at $33.37 and CTOR at $0.81 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

COLL vs CTOR Valuation Comparison 2026 — Intrinsic Value Analysis

COLL

Drug Manufacturers - Specialty & Generic

Collegium Pharmaceutical, Inc.

Quality

9.2

out of 10

Value Trap

SAFE

Price

$33.37

Last close

Models

12/13

Active

CTOR

Drug Manufacturers - Specialty & Generic

Citius Oncology, Inc.

Quality

3.4

out of 10

Value Trap

SAFE

Price

$0.81

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	COLL Fair Value	COLL Upside	CTOR Fair Value	CTOR Upside
Bayesian DCF	Intrinsic	$138.55	+315.2%	$0.23	-70.9%
Earnings Power Value	Intrinsic	$30.34	-9.1%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$27.72	-16.9%	$0.08	-91.8%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for COLL vs CTOR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

COLL vs CTOR — Which Stock Is More Undervalued?

COLL scores higher with a 9.2/10 quality rating vs CTOR's 3.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Collegium Pharmaceutical, Inc. (COLL) and Citius Oncology, Inc. (CTOR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

COLL currently trades at $33.37 with a QOC of 9.2/10, while CTOR trades at $0.81 with a QOC of 3.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).